Maturity onset diabetes of the young type 2 (MODY2): Insight from an extended family.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
May 2021
Historique:
received: 18 01 2021
revised: 18 03 2021
accepted: 30 03 2021
pubmed: 5 4 2021
medline: 16 7 2021
entrez: 4 4 2021
Statut: ppublish

Résumé

To assess long-term outcome of patients with maturity onset diabetes of the young, type 2 (MODY2) in a unique large cohort of patients with the same genetic and environmental background. We prospectively evaluated 162 patients aged 5 to 82 years, belonging to the same extended family living in the same village. All patients underwent molecular testing for the glucokinase (GCK) gene mutation identified in the proband, and were categorized into three groups (MODY2, type 2 diabetes and controls). The 5.5-year-old proband had the c.1278_1286del mutation in the GCK and was diagnosed with MODY2. Forty-two out of 162 participants were positive for the mutation and 39 had type 2 diabetes. Patients were followed for a mean 10.2 ± 3.7 years (range 0-14). Mean fasting blood glucose and HbA1c increased significantly over the years in MODY2 patients (133 vs. 146 mg/dL; 6.9% vs. 8.2%, respectively). Increase in HbA1c occurred only in the obese/overweight subgroups. Twenty-five percent of MODY2 patients developed diabetes complications, all were above 40 years of age. Although MODY2 commonly has a benign disease course, weight gain is a risk factor for diabetes complications, requiring life-long follow-up and in some patients, medical intervention.

Identifiants

pubmed: 33812904
pii: S0168-8227(21)00150-9
doi: 10.1016/j.diabres.2021.108791
pii:
doi:

Substances chimiques

Glucokinase EC 2.7.1.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108791

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Ghadir Elias-Assad (G)

Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel; The Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel. Electronic address: ghadir_ea@clalit.org.il.

Raunak Saab (R)

Baruch Padeh Medical Center, Poriya, Israel.

Janne Molnes (J)

KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.

Ora Hess (O)

Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel.

Rasmi Abu-Ras (R)

Faculty of Medicine, Bar-Ilan University, Zefat, Israel.

Hussein Darawshi (H)

Clalit Health Service, Northern district, Israel.

Pal Rasmus Njølstad (P)

KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway; Department of Pediatrics and Adolescents, Haukeland University Hospital, Bergen, Norway.

Yardena Tenenbaum-Rakover (Y)

Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel; The Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH